Print this article
- 12/06/2016

Takeda Pharmaceutical Company Limited is to invest €40m in a new facility

Pharma Horizon
Japanese pharma group Takeda is to invest €40 million in a new facility in Dublin in a move that will lead to the creation of 40 jobs.

The company, which set up operations in Ireland in 1997, is to build a new high-containment production centre to manufacture its oncology product Ninlaro at its Grange Castle site in Clondalkin.

Takeda is the largest pharmaceutical company in Japan. It employs more than 400 people at its three sites in Dublin.

Paul Keogh, plant director at Takeda Ireland Grange Castle, said that the additional investment in Ireland demonstrates the confidence and commitment the group has in its Irish operation.

“We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site,” he said.

The investment is supported IDA Ireland.

Welcoming the new investment by Takeda, Minister for Jobs, Enterprise and Innovation, Minister Mitchell O’Connor said, “The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors.”

She added, “Takeda’s decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I’m delighted that this investment will bring a further 40 jobs to the company’s existing Clondalkin facility.”


Source: The Irish Times